Tschöp, Matthias http://orcid.org/0000-0002-4744-371X
Nogueiras, Ruben http://orcid.org/0000-0002-9976-9930
Ahrén, Bo http://orcid.org/0000-0002-9804-5340
Funding for this research was provided by:
Medicinska Fakulteten, Lunds Universitet (314314)
Lund University
Article History
Received: 14 February 2023
Accepted: 27 March 2023
First Online: 20 May 2023
Authors’ relationships and activities
: MT is a member of the scientific advisory board of ERX Pharmaceuticals, Cambridge, MA. He was a member of the Research Cluster Advisory Panel (ReCAP) of the Novo Nordisk Foundation between 2017 and 2019. He attended a scientific advisory board meeting of the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, in 2016. He received funding for his research projects from Novo Nordisk (2016–2020) and Sanofi-Aventis (2012–2019). He has been a consultant for Bionorica (2013–2017), Menarini Ricerche (2016) and Bayer Pharma AG Berlin (2016). As former Director of the Helmholtz Diabetes Center and the Institute for Diabetes and Obesity at Helmholtz Zentrum München (2011–2018) and, since 2018, as CEO of Helmholtz Zentrum München, he has been responsible for collaborations with a multitude of companies and institutions worldwide. In this capacity, he discussed potential projects with and has signed/signs contracts for his institute(s) and for the staff for research funding and/or collaborations with industry and academia worldwide, including, but not limited to, pharmaceutical corporations such as Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Medigene, Arbormed and BioSyngen. In this role, he was/is further responsible for commercial technology transfer activities of his institute(s), including diabetes-related patent portfolios of Helmholtz Zentrum München, for example WO/2016/188,932 A2 and WO/2017/194,499 A1. BA has served as a speaker for Novo Nordisk during the last 12 months and owns stocks in Novo Nordisk, which produces GLP-1 receptor agonists. BA was also a member of the board of Novo Nordisk Foundation between 2006 and 2017. RN declares that there are no relationships or activities that might bias, or be perceived to bias, his work.
: All authors were responsible for drafting the article and revising it critically for important intellectual content. All authors approved the version to be published.